These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22405469)

  • 1. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma means no residual tumor: no need to assess "viability".
    Krasinskas AM
    Ann Diagn Pathol; 2012 Apr; 16(2):158-9. PubMed ID: 22405469
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with better prognosis.
    Wang H; Zhao Q
    Ann Diagn Pathol; 2012 Oct; 16(5):427. PubMed ID: 22561135
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
    Álvarez R; Alés I; Díaz R; de Paredes BG; Hidalgo M
    Clin Transl Oncol; 2017 Oct; 19(10):1193-1198. PubMed ID: 28612203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma.
    Silvestris N; Longo V; Cellini F; Reni M; Bittoni A; Cataldo I; Partelli S; Falconi M; Scarpa A; Brunetti O; Lorusso V; Santini D; Morganti A; Valentini V; Cascinu S
    Crit Rev Oncol Hematol; 2016 Feb; 98():309-24. PubMed ID: 26653573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.
    Winner M; Goff SL; Chabot JA
    Semin Oncol; 2015 Feb; 42(1):86-97. PubMed ID: 25726054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response assessment in pancreatic ductal adenocarcinoma: role of imaging.
    Baliyan V; Kordbacheh H; Parakh A; Kambadakone A
    Abdom Radiol (NY); 2018 Feb; 43(2):435-444. PubMed ID: 29243123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.
    Wang L; Niu W
    JAMA Surg; 2023 Jan; 158(1):102-103. PubMed ID: 36223123
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More Explorations Needed to Assess Matrix Metalloproteinase 7 Expression When Predicting the Pathologic Response to Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma-Reply.
    Shoucair S; Yu J
    JAMA Surg; 2023 Jan; 158(1):103-104. PubMed ID: 36223124
    [No Abstract]   [Full Text] [Related]  

  • 13. [Neoadjuvant treatment concepts for borderline-resectable adenocarcinoma of the pancreas].
    Roth S; Schneider M
    Chirurgie (Heidelb); 2022 Oct; 93(10):995-996. PubMed ID: 36063204
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.
    Pai RK; Pai RK
    Mod Pathol; 2018 Jan; 31(1):4-23. PubMed ID: 28776577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy for pancreatic cancer.
    Kleeff J; Friess H; Büchler MW
    Br J Surg; 2007 Mar; 94(3):261-2. PubMed ID: 17315287
    [No Abstract]   [Full Text] [Related]  

  • 16. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CRITICAL VIEWPOINT ON THE CURRENT APPROACH OF LOCALIZED PANCREATIC DUCTAL ADENOCARCINOMA].
    Van Daele D; Martinive P; Loly C; Polus M; Collignon J; Gast P; Louis E; Van Laethem JL
    Rev Med Liege; 2015 Nov; 70(11):540-5. PubMed ID: 26738264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Margin Status on Survival in Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Therapy.
    Swami A; Varshney VK
    J Am Coll Surg; 2021 Jun; 232(6):1022-1023. PubMed ID: 33722463
    [No Abstract]   [Full Text] [Related]  

  • 19. Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or 'all of the above'?
    Varadhachary GR; Evans DB
    Ann Surg Oncol; 2013 Nov; 20(12):3712-4. PubMed ID: 23943023
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic ductal carcinoma: from the bench to the bedside.
    Pezzilli R
    JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.